IFNG and neoplasm: In addition to tumor mutational burden (TMB), microsatellite instability, mismatch repair gene deficiency, T-cell inflamed and IFN-γ gene expression profiles (GEPs), and DNA damage response (DDR) and antigen presentation defects may serve as potential biomarkers for ICB therapy (7).